Wednesday, 3 June 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 03 June 2026
News

Aust added to drug licensing deal

Posted 3 June 2026 PM

Gedeon Richter has secured rights to Acrux’s Lenzetto, a transdermal estradiol spray, in an effort to address a critical shortage of menopause hormonal therapy (HRT) products in the Australian market.

Lenzetto, used for the treatment of symptoms associated with oestrogen deficiency occurring in women after menopause such as hot flushes, is already licensed to and marketed by Gedeon Richter in more than 40 countries with sales hitting 50 million euros in 2025.

To see the whole article, please login

Popular

GSK shuffles Govt Affairs team
Round 2: Blockbuster fight reignites
More Aussie pharma jobs go
'One-in-a-million' exec departs
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (18)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home